Metacrine, Inc.

The idea of an FXR agonist being the solution for treating metabolic function-associated steatohepatitis (MASH) took a substantial hit when Intercept Pharmaceuticals, Inc. ended development of obeti

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AbbVie Taps Anima’s mRNA Platform, Immu

Who: Equillium, Inc. / Metacrine, Inc. What: Equillium will acquire Metacrine in an all-stock transaction, but it will seek a strategic partner to develop the target company’s Phase II-ready FXR a

Twelve biopharmaceutical companies announced venture capital financings totaling $672m between 7 and 11 February, which was another relatively quiet week for public company offerings. With biotechnolo